Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

CDNA

Caredx Inc

Feb 13 • 04:00PM ET

19.63

+0.53 2.77 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: NTRA ILMN FLGT GH EXAS TWST VRTX CRSP TXG QGEN

| Held by: ARKG XBI VTI IWM VXF IWO IBB VTWO SCHA JSMD

Index	RUT	P/E	16.46	EPS (ttm)	1.19	Insider Own	10.86%	Shs Outstand	51.41M	Perf Week	0.82%
Market Cap	1.01B	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-0.78%	Shs Float	45.84M	Perf Month	-3.40%
Enterprise Value	843.04M	PEG	-	EPS next Q	0.02	Inst Own	97.68%	Short Float	12.55%	Perf Quarter	20.36%
Income	70.45M	P/S	2.82	EPS this Y	-132.13%	Inst Trans	0.34%	Short Ratio	7.55	Perf Half Y	66.07%
Sales	358.00M	P/B	3.24	EPS next Y	96.21%	ROA	15.50%	Short Interest	5.75M	Perf YTD	4.19%
Book/sh	6.05	P/C	5.20	EPS next 5Y	-	ROE	24.11%	52W High	25.55 -23.17%	Perf Year	-20.97%
Cash/sh	3.78	P/FCF	27.22	EPS past 3/5Y	- -	ROIC	21.20%	52W Low	10.96 79.11%	Perf 3Y	30.35%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.04% 21.31%	Gross Margin	66.92%	Volatility	6.67% 5.47%	Perf 5Y	-78.04%
Dividend TTM	-	EV/Sales	2.35	EPS Y/Y TTM	148.22%	Oper. Margin	-7.01%	ATR (14)	1.15	Perf 10Y	284.90%
Dividend Ex-Date	-	Quick Ratio	2.75	Sales Y/Y TTM	14.46%	Profit Margin	19.68%	RSI (14)	49.09	Recom	2.11
Dividend Gr. 3/5Y	- -	Current Ratio	3.03	EPS Q/Q	122.29%	SMA20	-2.50%	Beta	2.51	Target Price	24.00
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	20.72%	SMA50	-0.25%	Rel Volume	0.61	Prev Close	19.10
Employees	650	LT Debt/Eq	0.07	Earnings	Feb 24 AMC	SMA200	18.26%	Avg Volume	762.12K	Price	19.63
IPO	Jul 17, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	136.63% 4.91%	Trades		Volume	464,003	Change	2.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-26	Downgrade	Craig Hallum	Buy → Hold	$26
Aug-26-25	Initiated	William Blair	Mkt Perform
Jan-15-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$28 → $24
Aug-28-24	Initiated	Wells Fargo	Underweight	$28
Aug-19-24	Upgrade	BTIG Research	Neutral → Buy	$40
May-13-24	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-24	Upgrade	Craig Hallum	Hold → Buy	$15
Nov-09-23	Upgrade	Stephens	Equal-Weight → Overweight	$10
Aug-15-23	Upgrade	Raymond James	Mkt Perform → Outperform	$12
May-11-23	Downgrade	BTIG Research	Buy → Neutral
Mar-07-23	Downgrade	Stephens	Overweight → Equal-Weight	$19 → $9
Mar-03-23	Downgrade	Raymond James	Strong Buy → Mkt Perform
Mar-03-23	Downgrade	Craig Hallum	Buy → Hold	$26 → $9
Apr-25-22	Initiated	Stephens	Overweight	$50
Jul-20-21	Resumed	BTIG Research	Buy	$115
Jun-03-21	Initiated	Goldman	Buy	$95
Feb-26-21	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-30-20	Reiterated	H.C. Wainwright	Buy	$47 → $55
Oct-08-20	Reiterated	H.C. Wainwright	Buy	$45 → $47
Oct-02-20	Reiterated	H.C. Wainwright	Buy	$40 → $45

Show Previous Ratings

Feb-13-26 01:09AM	CareDx Expands Transplant Plus Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data (MarketBeat)
Feb-12-26 07:05AM	CareDx Announces Clinical Validation Results for AlloHeme, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy (Business Wire)
Feb-10-26 04:01PM	CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (Business Wire)
Feb-03-26 07:05AM	CareDx to Present AlloHeme Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings (Business Wire)
Jan-27-26 04:05PM	CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
10:45AM	Loading…
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:30AM	Implied Volatility Surging for CareDx Stock Options (Zacks)
Jan-12-26 08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks) +20.08%
07:05AM	CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-07-26 07:05AM	CareDx and 10x Genomics to Launch ImmuneScape Program - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response (Business Wire)
Jan-06-26 10:48AM	Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now? (Zacks) -5.05%
Dec-26-25 04:05PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-23-25 09:15AM	Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-18-25 05:00PM	CareDx Provides Notice of Proposed Derivative Settlement (Business Wire)
Nov-27-25 09:55AM	Wall Street Analysts Believe CareDx (CDNA) Could Rally 28.02%: Here's is How to Trade (Zacks)
04:05PM	Loading…
Nov-24-25 04:05PM	SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation (Business Wire)
Nov-07-25 04:05PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.91%
Nov-06-25 08:00AM	CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025 (Business Wire) -9.20%
Nov-05-25 12:03AM	CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance (GuruFocus.com) +13.84%
Nov-04-25 07:00PM	CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:15PM	CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
05:12PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Announces Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 07:52AM	CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 07:05AM	CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer (Business Wire)
Oct-23-25 04:05PM	CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure (Business Wire)
Oct-22-25 04:01PM	CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors (Business Wire)
Oct-21-25 08:00AM	CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-06-25 07:05AM	CareDx Announces New IVD Products and IVDR Certification for AlloSeq Tx and QTYPE at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting (Business Wire)
Sep-02-25 04:01PM	CareDx Issues Comment Letter on Draft LCD Policy (Business Wire) -8.09%
01:08PM	Loading…
Aug-26-25 01:08PM	CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential (Benzinga)
Aug-22-25 08:30AM	Do Options Traders Know Something About CareDx Stock We Don't? (Zacks)
Aug-21-25 04:01PM	CareDx to Participate in Wells Fargo Healthcare Conference (Business Wire)
Aug-12-25 08:00AM	Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire) +5.86%
Aug-06-25 06:30PM	Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings (Zacks) -7.86%
05:45PM	CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates (Zacks)
04:57PM	CareDx Announces Appointment of Nathan Smith as Chief Financial Officer (Business Wire)
04:43PM	CareDx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	CareDx Announces Second Quarter 2025 Financial Results (Business Wire)
12:56PM	CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation (Business Wire)
Aug-05-25 10:07AM	What To Expect From CareDx Inc (CDNA) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 04:01PM	CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress (Business Wire)
Jul-23-25 07:05AM	CareDx to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-22-25 07:06AM	CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains? (Zacks)
Jul-18-25 08:00AM	CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection (Business Wire)
Jun-03-25 04:30PM	CareDx Announces Repurchase of 5% of Outstanding Shares (Business Wire) +10.67%
May-13-25 04:01PM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
May-01-25 03:17AM	CareDx Inc (CDNA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments (GuruFocus.com) -10.72%
Apr-30-25 08:39PM	CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript (Seeking Alpha) -6.89%
05:50PM	CareDx (CDNA) Tops Q1 Earnings Estimates (Zacks)
04:50PM	CareDx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports First Quarter 2025 Results (Business Wire)
Apr-29-25 07:05AM	CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-24-25 07:05AM	CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-21-25 04:01PM	CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-08-25 07:05AM	CareDx to Report First Quarter 2025 Financial Results (Business Wire)
Apr-04-25 12:40PM	Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-11-25 07:05AM	CareDx Launches Two Expanded Indications for AlloSure Testing Services (Business Wire)
Feb-27-25 02:20AM	CareDx Inc (CDNA) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-26-25 07:00PM	CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:56PM	CareDx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-25-25 10:39AM	CareDx Inc (CDNA) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:05AM	CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict (Business Wire)
Feb-20-25 07:05AM	CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients (Business Wire) -5.34%
Feb-13-25 07:05AM	CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies (Business Wire)
Feb-11-25 07:05AM	CareDx to Report Fourth Quarter and Full Year 2024 Financial Results (Business Wire) -8.43%
03:22AM	CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Feb-10-25 02:51PM	Trade Tracker: Amy Raskin trims Vertex, Natera & Kadant, buys CareDx and Impinj (CNBC TV) +11.16%
02:51PM	Final Trades: NRG Energy, MP Materials, CareDx and Applovin (CNBC TV)
Feb-05-25 09:55AM	Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect? (Zacks)
Jan-29-25 09:40AM	Is CareDx (CDNA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-28-25 08:19AM	CareDx (CDNA) Traded Down Due to Disappointing Quarterly Results (Insider Monkey)
Jan-24-25 08:35AM	Heres Why CareDx (CDNA) Traded Lower in Q4 (Insider Monkey)
Jan-15-25 03:50PM	Wells Fargo upgrades CareDx after a 30% pullback in stock (Investing.com)
Jan-14-25 03:43AM	Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength? (Zacks) -12.05%
Jan-13-25 07:00AM	CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results (Business Wire) +6.09%
Jan-06-25 09:35AM	Implied Volatility Surging for CareDx (CDNA) Stock Options (Zacks)
Dec-18-24 07:05AM	CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.86%
Dec-11-24 07:00AM	TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (PR Newswire)
07:00AM	CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (Business Wire)
Dec-03-24 09:40AM	Has CareDx (CDNA) Outpaced Other Medical Stocks This Year? (Zacks)
Nov-29-24 10:46AM	Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA) (Insider Monkey)
Nov-25-24 09:55AM	Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know (Zacks)
Nov-15-24 09:35AM	After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA) (Zacks)
Nov-14-24 09:40AM	Are Medical Stocks Lagging CareDx (CDNA) This Year? (Zacks) -5.40%
Nov-12-24 07:05AM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
Nov-07-24 09:04AM	Accelerated Testing Volume Lifted CareDx (CDNA) in Q3 (Insider Monkey)
Nov-05-24 01:03PM	Q3 2024 CareDx Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Nov-04-24 05:03PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance (Business Wire)
Oct-23-24 07:00AM	CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology (Business Wire)
Oct-21-24 07:00AM	CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting (Business Wire)
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in CareDx Inc Holdings (GuruFocus.com) -6.49%
Oct-16-24 08:17AM	CareDx Reports Strong Q3 2024 Revenue Growth (TipRanks)
Oct-15-24 06:00AM	CareDx Reports Preliminary Financial Results for Third Quarter 2024 (Business Wire) -15.84%
Oct-11-24 04:30PM	CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 03:35PM	CareDx Inc (CDNA) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Positive Adjusted ... (GuruFocus.com) -12.42%
07:05AM	CareDx Appoints Jing Huang Chief Data and AI Officer (Business Wire)

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novack Jeffrey Adam	Secretary and General Counsel	Feb 03 '26	Sale	20.56	4,441	91,286	125,364	Feb 04 04:22 PM
JEFFREY NOVACK	Officer	Feb 03 '26	Proposed Sale	20.42	4,441	90,685		Feb 03 04:33 PM
Hanna John Walter JR	President and CEO	Jan 22 '26	Sale	21.16	19,280	408,023	597,405	Jan 23 05:58 PM
Hanna John Walter JR	President and CEO	Jan 21 '26	Sale	21.00	200	4,200	616,685	Jan 23 05:58 PM
Hanna John Walter JR	President and CEO	Jan 15 '26	Sale	21.05	10,156	213,804	616,885	Jan 20 05:30 PM
JOHN HANNA	Director	Jan 15 '26	Proposed Sale	20.32	29,636	602,204		Jan 15 04:40 PM
Novack Jeffrey Adam	Secretary and General Counsel	Dec 04 '25	Sale	19.17	7,293	139,804	97,925	Dec 05 04:07 PM
JEFFREY NOVACK	Officer	Dec 04 '25	Proposed Sale	18.85	7,293	137,473		Dec 04 04:39 PM
Novack Jeffrey Adam	Secretary and General Counsel	Nov 07 '25	Sale	15.52	2,688	41,723	105,218	Nov 10 04:14 PM
Jeffrey Adam Novack	Officer	Nov 07 '25	Proposed Sale	15.01	2,688	40,347		Nov 07 04:37 PM
ABHISHEK JAIN	Officer	Nov 05 '25	Proposed Sale	15.77	53,388	842,050		Nov 05 04:21 PM
ABHISHEK JAIN	Officer	Oct 31 '25	Proposed Sale	14.90	9,964	148,464		Oct 31 04:48 PM
Bickerstaff George	Director	Sep 11 '25	Option Exercise	7.96	29,136	231,923	144,266	Sep 12 05:09 PM
Novack Jeffrey Adam	Secretary and General Counsel	Aug 05 '25	Sale	12.79	2,688	34,381	112,930	Aug 07 04:00 PM
Jeffrey Adam Novack	Officer	Aug 05 '25	Proposed Sale	12.60	2,688	33,869		Aug 05 04:27 PM
Maag Peter	Director	Jul 07 '25	Sale	18.58	10,000	185,831	308,846	Jul 10 04:04 PM
Valantine Hannah	Director	Jun 18 '25	Sale	19.16	10,570	202,566	38,994	Jun 23 04:30 PM
Maag Peter	Director	Jun 17 '25	Sale	19.24	10,000	192,420	318,846	Jun 20 04:30 PM
HANNAH VALANTINE	Director	Jun 18 '25	Proposed Sale	19.52	10,570	206,326		Jun 18 04:26 PM
HAGSTROM WILLIAM A	Director	Jun 11 '25	Option Exercise	13.20	19,391	256,052	73,370	Jun 13 05:06 PM
HAGSTROM WILLIAM A	Director	Jun 11 '25	Sale	19.90	19,391	385,918	53,979	Jun 13 05:06 PM
WILLIAM HAGSTROM	Director	Jun 11 '25	Proposed Sale	19.90	19,391	385,918		Jun 11 04:20 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Option Exercise	7.45	30,000	223,441	83,979	May 30 05:57 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Sale	17.45	30,000	523,413	53,979	May 30 05:57 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Proposed Sale	17.63	30,000	528,900		May 28 05:01 PM
COURNOYER CHRISTINE	Director	May 12 '25	Option Exercise	7.96	29,136	231,923	66,181	May 14 05:18 PM
COURNOYER CHRISTINE	Director	May 12 '25	Sale	15.96	29,136	465,022	37,045	May 14 05:18 PM
COURNOYER CHRISTINE	Director	May 12 '25	Proposed Sale	15.96	29,136	465,021		May 12 05:15 PM
Christine M. Cournoyer	Director	May 12 '25	Proposed Sale	15.36	12,000	184,320		May 12 05:10 PM
COURNOYER CHRISTINE	Director	May 06 '25	Sale	14.13	16,700	235,929	37,045	May 08 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	May 05 '25	Sale	14.70	2,688	39,514	121,350	May 07 04:38 PM
Christine M. Cournoyer	Director	May 06 '25	Proposed Sale	15.17	16,700	253,339		May 06 05:00 PM
Jeffrey Adam Novack	Officer	May 05 '25	Proposed Sale	15.00	2,688	40,320		May 05 04:39 PM
Maag Peter	Director	Apr 30 '25	Sale	17.23	13,281	228,796	316,743	May 02 04:49 PM
PETER MAAG	Director	Apr 30 '25	Proposed Sale	18.13	33,281	603,385		Apr 30 04:18 PM
Jain Abhishek	Chief Financial Officer	Apr 07 '25	Sale	17.72	265	4,696	337,418	Apr 09 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	Apr 07 '25	Sale	17.72	924	16,373	126,911	Apr 09 04:30 PM
Bickerstaff George	Director	Mar 10 '25	Sale	18.36	20,000	367,102	103,027	Mar 12 04:30 PM
GEORGE W BICKERSTAFF	Director	Mar 10 '25	Proposed Sale	18.36	20,000	367,102		Mar 10 05:03 PM

Open in Screener

INVA

Innoviva Inc

Feb 13 • 04:00PM ET

22.70

+0.26 1.16 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD MRK ABBV AMGN REGN BIIB BMY VRTX PFE SAN

| Held by: IJR VTI AVUV IWM VB VBR VXF SPSM PJP DFAT

Index	RUT	P/E	16.28	EPS (ttm)	1.39	Insider Own	1.16%	Shs Outstand	74.77M	Perf Week	4.13%
Market Cap	1.70B	Forward P/E	10.60	EPS next Y	2.14	Insider Trans	0.00%	Shs Float	73.90M	Perf Month	14.99%
Enterprise Value	1.42B	PEG	0.13	EPS next Q	0.60	Inst Own	105.94%	Short Float	8.28%	Perf Quarter	1.89%
Income	127.34M	P/S	4.22	EPS this Y	441.67%	Inst Trans	8.15%	Short Ratio	7.40	Perf Half Y	8.72%
Sales	402.32M	P/B	1.68	EPS next Y	9.87%	ROA	9.57%	Short Interest	6.12M	Perf YTD	13.56%
Book/sh	13.51	P/C	3.18	EPS next 5Y	84.11%	ROE	15.17%	52W High	23.42 -3.07%	Perf Year	24.59%
Cash/sh	7.13	P/FCF	8.46	EPS past 3/5Y	-49.84% -24.00%	ROIC	10.04%	52W Low	16.52 37.41%	Perf 3Y	84.25%
Dividend Est.	-	EV/EBITDA	6.84	Sales past 3/5Y	-2.80% 6.27%	Gross Margin	77.05%	Volatility	3.84% 2.77%	Perf 5Y	87.60%
Dividend TTM	-	EV/Sales	3.54	EPS Y/Y TTM	88.06%	Oper. Margin	41.73%	ATR (14)	0.63	Perf 10Y	89.32%
Dividend Ex-Date	Sep 08, 2015	Quick Ratio	13.33	Sales Y/Y TTM	9.76%	Profit Margin	31.65%	RSI (14)	79.39	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.12	EPS Q/Q	5503.63%	SMA20	9.57%	Beta	0.42	Target Price	32.50
Payout	0.00%	Debt/Eq	0.26	Sales Q/Q	19.68%	SMA50	11.76%	Rel Volume	0.65	Prev Close	22.44
Employees	127	LT Debt/Eq	0.26	Earnings	Nov 05 AMC	SMA200	15.20%	Avg Volume	826.56K	Price	22.70
IPO	Oct 05, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	134.78% 17.99%	Trades		Volume	538,818	Change	1.16%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Initiated	Goldman	Sell	$17
Aug-11-25	Initiated	Oppenheimer	Outperform	$45
Jul-14-25	Initiated	H.C. Wainwright	Buy	$40
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight	$26
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$55
Jun-18-24	Initiated	Cantor Fitzgerald	Overweight
Jul-20-22	Initiated	Goldman	Neutral	$16
Nov-20-17	Initiated	Deutsche Bank	Hold	$13

Feb-04-26 07:55AM	Eli Lilly (LLY) Q4 Earnings and Revenues Beat Estimates (Zacks)
Jan-08-26 08:23AM	Biotech Is Heating Up-These 2 Red-Hot Stocks Stand Out (MarketBeat)
Dec-21-25 09:57AM	H.C. Wainwright Lifts PT on Innoviva (INVA) to $46 From $45, Keeps a Buy Rating (Insider Monkey)
Dec-12-25 04:56PM	U.S. FDA Approves NUZOLVENCE (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents (Business Wire)
Dec-11-25 06:35PM	Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea (Business Wire)
07:00AM	Loading…
Nov-25-25 07:00AM	Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference (Business Wire)
Nov-14-25 04:47AM	Beacon Biosignals secures $86m to advance AI-driven brain biomarker use (Medical Device Network)
Nov-05-25 06:40PM	Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates (Zacks) +12.89%
05:33PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Nov-04-25 08:00AM	Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-31-25 09:00AM	AbbVie (ABBV) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-30-25 07:55AM	Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-23-25 05:02AM	Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength? (Zacks)
Oct-21-25 08:00AM	Antheia Appoints Eric d'Esparbes as Chief Financial Officer (PR Newswire)
08:00AM	Loading…
Oct-20-25 08:00AM	Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 (Business Wire)
Oct-14-25 07:30AM	Johnson & Johnson (JNJ) Beats Q3 Earnings and Revenue Estimates (Zacks)
Oct-10-25 06:21AM	New Strong Buy Stocks for October 10th (Zacks)
Oct-07-25 09:40AM	Are Investors Undervaluing Innoviva (INVA) Right Now? (Zacks)
08:00AM	Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 (Business Wire)
Sep-17-25 02:27PM	Where is Innoviva (INVA) Headed According to Analysts? (Insider Monkey)
Aug-26-25 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Aug-13-25 08:00AM	Innoviva Specialty Therapeutics Antimicrobial Therapies ZEVTERA and XACDURO Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award (Business Wire)
Aug-12-25 04:05PM	Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update (PR Newswire)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly) +7.14%
Aug-06-25 05:06PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Jun-12-25 07:00AM	FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025 (Business Wire)
Jun-10-25 06:00AM	Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults (Business Wire)
Jun-03-25 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
06:00AM	Loading…
May-20-25 06:00AM	ZEVTERA (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections (Business Wire)
May-08-25 08:54AM	Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling (Insider Monkey)
May-07-25 05:52PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress (Business Wire)
Apr-11-25 12:30AM	Harbor Health Care ETF Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 06:35PM	Victorias Secret, Bitdeer, and More Stocks See Activist Action (Barrons.com)
Mar-14-25 06:17PM	WEX, Lamb Weston, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-12-25 05:08PM	Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva (PR Newswire)
Mar-05-25 07:00AM	Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference (Business Wire)
Feb-26-25 04:35PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:04PM	Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-06-25 07:00AM	Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-17-24 07:25AM	Innoviva enters distribution, license agreement with Basilea for Zevtera (TipRanks)
Dec-16-24 07:00AM	Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera (ceftobiprole) (Business Wire)
01:15AM	Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera (ceftobiprole) in the United States (GlobeNewswire)
Nov-26-24 07:00AM	Innoviva to Participate in the Citi 2024 Global Healthcare Conference (Business Wire)
Nov-21-24 11:14PM	Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity (PR Newswire)
Nov-12-24 04:05PM	Innoviva to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-06-24 05:23PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Sep-04-24 07:00AM	Innoviva to Participate in Upcoming Investor Conferences (Business Wire)
Jul-31-24 10:54PM	INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:51PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
Jul-09-24 01:30PM	The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 (InvestorPlace)
Jun-27-24 08:00AM	3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge (InvestorPlace)
Jun-18-24 09:51AM	Apple downgraded, Kroger upgraded: Wall Street's top analyst calls (The Fly)
Jun-03-24 07:00AM	Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-31-24 07:30AM	3 Under-$20 Stocks That Could Make You a Fortune (InvestorPlace)
May-20-24 04:06AM	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment (MT Newswires)
May-10-24 02:04PM	Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis (GuruFocus.com)
May-08-24 10:57PM	INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:09PM	Innoviva: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress (Business Wire)
07:00AM	Innoviva to Participate in the BofA Securities Health Care Conference (Business Wire)
Apr-24-24 07:00AM	Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 (Business Wire)
Mar-04-24 04:01PM	Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva (PR Newswire)
Feb-29-24 04:56PM	Innoviva: Q4 Earnings Snapshot (Associated Press Finance)
04:37PM	Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress (Business Wire)
Feb-14-24 02:44AM	Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition (GuruFocus.com)
Jan-10-24 06:16PM	If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names (InvestorPlace)
Nov-18-23 07:03AM	Insider Sell Alert: Marianne Zhen Offloads Shares of Innoviva Inc (GuruFocus.com)
Nov-03-23 06:00AM	Innoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 Million (GuruFocus.com)
Nov-01-23 05:32PM	Innoviva: Q3 Earnings Snapshot (Associated Press Finance) +6.92%
04:15PM	Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
04:05PM	Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea (Business Wire)
Sep-19-23 08:30AM	Innoviva to Participate in the Cantor Global Healthcare Conference (Business Wire)
Sep-18-23 08:00AM	XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults (Business Wire)
Aug-25-23 04:52PM	Innoviva Appoints Stephen Basso as Chief Financial Officer (Business Wire)
Aug-02-23 05:18PM	Innoviva: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-23-23 09:22AM	Investors in Innoviva (NASDAQ:INVA) have unfortunately lost 11% over the last year (Simply Wall St.)
Jul-11-23 08:53PM	Why These 7 Stocks Are the Best Ways to Play Biotech Right Now (InvestorPlace)
08:00AM	Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics (PR Newswire)
Jul-06-23 11:33AM	12 Best Extremely Profitable Stocks to Buy (Insider Monkey)
Jun-26-23 01:27AM	Insider trades & hedge fund hits: Elliott aims to oust NRG chief (Investing.com)
Jun-21-23 08:00PM	INVA: What does Argus have to say about INVA? (Argus Research)
Jun-07-23 08:30AM	Do Its Financials Have Any Role To Play In Driving Innoviva, Inc.'s (NASDAQ:INVA) Stock Up Recently? (Simply Wall St.)
Jun-06-23 04:05PM	Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference (Business Wire)
May-24-23 01:49PM	AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter (Benzinga)
May-23-23 06:42PM	Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use (Business Wire)
May-11-23 06:45PM	Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases (Business Wire)
07:42AM	Is There An Opportunity With Innoviva, Inc.'s (NASDAQ:INVA) 35% Undervaluation? (Simply Wall St.)
May-09-23 07:45PM	Innoviva: Q1 Earnings Snapshot (AP Finance) +5.54%
04:32PM	Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Apr-28-23 05:30PM	Innoviva Announces Retirement of Board Chairman (Business Wire)
Apr-26-23 08:00PM	INVA: Lowering target price to $9.00 (Argus Research)
Apr-18-23 11:22AM	FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections (Benzinga) -5.16%
Apr-17-23 04:31PM	Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee (Business Wire)

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DENNER ALEXANDER J	10% Owner	Mar 06 '25	Sale	17.52	1,196,746	20,964,237	5,658,705	Mar 06 09:30 PM
DENNER ALEXANDER J	10% Owner	Mar 05 '25	Sale	17.63	270,374	4,766,126	6,855,451	Mar 06 09:30 PM
DENNER ALEXANDER J	10% Owner	Mar 04 '25	Sale	17.63	151,175	2,665,079	7,125,825	Mar 06 09:30 PM

CDNA

Caredx Inc

INVA

Innoviva Inc

Upgrade your FINVIZ experience